For the quarter ending 2026-03-31, STRO had $15,552K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | -76,314 | - | 90,837 | - |
| Personnel-related expenses | -52,743 | - | 66,680 | - |
| Outside services | -33,002 | - | 55,077 | - |
| Preclinical research and clinical development expenses | -4,378 | - | 5,623 | - |
| Laboratory supplies | -8,588 | - | 9,201 | - |
| Facility and maintenance expenses | -8,069 | - | 11,129 | - |
| Equipment and office-related expenses | -10,675 | - | 13,768 | - |
| Travel-related expenses | -540 | - | 654 | - |
| Restructuring and related costs | -48,981 | - | 49,023 | - |
| Operating expenses | -166,976 | - | 211,155 | - |
| Loss from operations | 90,662 | - | -120,318 | - |
| Non-cash interest expense related to the sale of future royalties | -19,194 | - | 28,661 | - |
| Revenue | - | 102,484 | - | - |
| Interest income | -6,082 | - | 7,717 | - |
| Operating expenses | - | 260,851 | - | - |
| Interest and other income (expense), net | 2,062 | - | -3,073 | - |
| Loss from operations | - | -158,367 | - | - |
| Non-operating loss | 15,174 | - | -24,017 | - |
| Impairment charges | - | 1,694 | - | - |
| Loss before provision for income taxes | -38,499 | -46,844 | -144,335 | - |
| Realized gain on sale of equity securities | - | 0 | - | - |
| Income tax expense | - | -93 | - | - |
| Income tax benefits (expense) | -4 | - | -11 | - |
| Unrealized gain on equity securities | - | 0 | 0 | 0 |
| Net loss | -38,484 | -46,762 | -56,857 | -87,467 |
| Depreciation and amortization | 1,278 | 1,624 | 1,900 | 3,800 |
| Accretion of discount on marketable securities | 445 | 531 | 755 | 2,149 |
| Stock-based compensation | 1,562 | 1,655 | 1,552 | 10,801 |
| Non-cash lease expenses | 1,196 | 1,548 | 1,495 | 2,841 |
| Non-cash interest expense on deferred royalty obligation | 9,467 | 9,547 | 9,670 | 18,991 |
| Other | -109 | -111 | -157 | -303 |
| Accounts receivable | 8,507 | 55 | -4,077 | -617 |
| Prepaid expenses and other assets | 1,003 | -4,976 | -7,953 | -6,421 |
| Accounts payable | -2,547 | 575 | 2,683 | -5,726 |
| Accrued compensation | -9,288 | 1,394 | 1,484 | -1,141 |
| Accrued expenses and other liabilities | 8,403 | -79 | -3,481 | 7,112 |
| Deferred revenue | -1,958 | -145 | -6,135 | -63,449 |
| Operating lease liability | -2,042 | -1,987 | -1,932 | -3,561 |
| Net cash used in operating activities | -42,259 | -26,435 | -38,189 | -112,607 |
| Purchases of marketable securities | 124,703 | 4,039 | 89,938 | 170,973 |
| Maturities of marketable securities | 76,210 | 2,500 | 115,516 | 135,750 |
| Sales of marketable securities | 3,240 | 20,425 | 14,662 | 22,805 |
| Proceeds from sale of equity securities, net | - | 0 | 0 | - |
| Purchases of equipment and leasehold improvements | 11 | 184 | 251 | 1,260 |
| Net cash used in investing activities | -45,264 | 18,702 | 39,989 | -13,678 |
| Proceeds from sales of common stock to ipsen biopharmaceuticals, inc. (usa) | - | 0 | 0 | 0 |
| Payments of debt | - | 0 | 0 | 0 |
| Proceeds from sales of common stock, net of issuance costs | 103,126 | 0 | 0 | 0 |
| Proceeds from exercise of common stock options | 28 | 3 | 1 | 0 |
| Taxes paid related to net shares settlement of restricted stock units | 160 | 67 | 25 | 240 |
| Proceeds from employee stock purchase plan | 81 | 0 | 126 | 246 |
| Net cash provided by financing activities | 103,075 | -64 | 102 | 6 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 15,552 | -7,797 | 1,902 | -126,279 |
| Cash, cash equivalents and restricted cash at beginning of period | 58,988 | 66,785 | 191,162 | - |
| Cash, cash equivalents and restricted cash at end of period | 74,540 | 58,988 | 66,785 | - |